Recent events
Recent events tied to this brand in public sources.
Back to profile24 entries · Page 1 of 2
2026
Illumina selected to provide sequencing services for Singapore’s SG-INSIGHT study
Illumina announced that it had been selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, part of Phase III of the country’s National Precision Medicine programme. The study is expected to include approximately 450,000 individuals.
2026
Illumina raises fiscal 2026 revenue and earnings guidance
Illumina announced it was raising its full-year revenue and earnings guidance. Its updated fiscal 2026 outlook included total revenue of $4.64–$4.66 billion and non-GAAP diluted EPS of $5.40–$5.45.
2026
Illumina reports third-quarter fiscal 2026 results
Illumina announced its financial results for the third quarter of fiscal year 2026, reporting revenue of $1.13 billion.
2026
Illumina launches BioInsight Platform, its first unified software environment
Illumina debuted the BioInsight Platform, its first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful biological evidence. The launch includes the newly released DRAGEN v4.6 with expanded cloud and standard CPU deployment options, and replaces traditional annual subscriptions with a usage-based BioInsight Credits model.
2026
Illumina launches SpliceAI2 genomic AI model for rare disease research
Illumina announced on October 8, 2026 the launch of SpliceAI2, a new genomic AI model for predicting the functional splicing effects of genetic variants. In a rare disease research dataset, SpliceAI2 identified 17% more disease-related variants than other splicing models; researchers in rare disease and drug discovery can access it through Illumina BioInsight applications including DRAGEN Annotation and Emedgene.
2022
Illumina files trade-secrets lawsuit against Guardant Health
Illumina filed a lawsuit against Guardant Health, alleging that Guardant's co-founders took confidential Illumina documents and that patents central to Guardant's cancer-detection work relied on that information. Guardant disputed Illumina's claims and said they had no merit.
2022
Illumina agrees to support a French genomic-profiling study
Illumina announced an agreement with the Jean Perrin Center to assess the clinical value of comprehensive genomic profiling for therapy options in patients with late-stage cancer. Illumina is providing sequencing reagents and biostatistician expertise for the study.
2022
Illumina and National Cancer Center Japan announce international research collaboration
Illumina and the National Cancer Center Japan announced an international joint research project using Illumina sequencing technology to study patients with nasopharyngeal carcinoma and support development of personalized treatments.
2022
Illumina and Agendia announce multi-year partnership
Illumina announced a multi-year partnership with Agendia to co-develop in vitro diagnostic tests for oncology testing, including plans to develop tests for breast cancer using Illumina’s MiSeqDx platform.
2022
Illumina and Nashville Biosciences announce genomics collaboration
Illumina and Nashville Biosciences announced a multi-year agreement to advance medicines development through large-scale genomics and establish a clinico-genomic resource. Illumina will sequence samples from Vanderbilt University Medical Center’s biobank and upload the data to its analytics platform.
2022
SomaLogic and Illumina partner on co-branded sequencing platform
SomaLogic and Illumina entered a partnership to develop and bring to market a co-branded next-generation sequencing platform. Illumina will develop and deploy protein identification and measurement tools into laboratories worldwide.
2021
Illumina appoints Bob Ragusa as GRAIL CEO
Illumina announced that Bob Ragusa was appointed Chief Executive Officer of GRAIL, effective immediately. Hans Bishop stepped down and was to serve as an advisor through the end of 2021.
2021
Illumina and Merck announce HRD testing partnership
Illumina and Merck announced a partnership to develop and commercialize tests that identify genetic mutations used in assessing homologous recombination deficiency. Illumina will develop an HRD companion diagnostic test for the EU and UK and a research-use-only HRD assay for planned global availability excluding the United States and Japan.
2021
Illumina completes acquisition of Grail
Illumina announced that it had completed its acquisition of cancer-screening company Grail for $8 billion while U.S. and European regulatory reviews were ongoing. The article also reports that the U.S. Federal Trade Commission had opposed the transaction, alleging it could weaken innovation in U.S. multi-cancer early-detection technology.
2021
Sanigen becomes Illumina channel partner in South Korea
Sanigen announced that it would become Illumina's channel partner in South Korea. The companies said they would work together to deliver Illumina's NGS platform technology to the food safety and microbiology sector there.
2021
FTC sues to block Illumina’s acquisition of Grail
The U.S. Federal Trade Commission filed a lawsuit seeking to block Illumina’s acquisition of Grail. The FTC said the acquisition could hinder innovation in multi-cancer detection; this is the regulator’s stated concern, not a court determination.
2020
Emedgene and Illumina announce a partnership and software integration
Emedgene announced a non-exclusive partnership with Illumina and the integration of automated genomic interpretation into Illumina's TruSight Software Suite for rare genetic diseases.
2020
Illumina announces acquisition of Grail
Illumina announced an $8 billion cash-and-stock acquisition of cancer-screening startup Grail, describing the deal as its entry into the early cancer screening field.
2020
Imagia and Illumina announce a partnership
Imagia and Illumina announced a partnership to investigate how genomics, clinical data and imaging can enable precision medicine and improve patient outcomes.
2020
Illumina acquires BlueBee
Illumina acquired BlueBee, a cloud software company that provides genomic analysis solutions to research and clinical customers. The acquisition adds BlueBee's cloud capabilities to Illumina's analytics offering; the terms were not disclosed.